Petros Pharmaceuticals, Inc.
Petros Pharmaceuticals, Inc. is a U.S.-based pharmaceutical company organized around prescription erectile dysfunction products and related men’s health devices. The company has operated through subsidiaries including Metuchen Pharmaceuticals, Timm Medical Technologies, and Pos-T-Vac, with activities historically centered on Stendra® and vacuum erection devices.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2021–2025
Liiketoiminta
Osuus liikevaihdostaPrescription erectile dysfunction therapy historically commercialized under the Stendra® brand.
Mechanical erectile dysfunction devices sold through Timm Medical and Pos-T-Vac.
Development efforts aimed at nonprescription pharmaceutical products and ACNU treatments.
Asiakkaat
The company’s historical customers include adult men seeking treatment for erectile dysfunction through prescription or device-based options. Its products have also been sold through wholesalers, retailers, and other distribution channels that serve pharmacies and men’s health markets. The emerging self-care focus is aimed at consumers and channel partners that support nonprescription access to selected pharmaceutical products.
Men seeking prescription or device-based erectile dysfunction treatment.
Buy and distribute Stendra® and related pharmaceutical products through commercial channels.
Purchase VED products for resale to men’s health consumers.
Future target users for nonprescription pharmaceutical products and ACNU offerings.
Strategia
Petros is repositioning its business toward nonprescription pharmaceuticals and ACNU products while evaluating internal development, collaborations, and acquisitions. The strategy depends on securing capital and external partners to build a new commercial platform after the historical ED and device businesses were discontinued or assigned away.
The company is trying to replace legacy ED revenue with self-care products that can be commercialized through broader consumer channels.
External deals can add products, rights, or capabilities faster than internal development alone.
Development and commercialization require capital before new products can generate meaningful revenue.
Maantiede
Q3/2024Petros is a U.S.-based company with operations and commercial activity historically centered in the United States. Its products have been marketed in U.S. pharmaceutical and device channels, and the company’s corporate structure is organized through Delaware-based parent and operating subsidiaries.
Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.
Riskit
Petros faces substantial going-concern and financing risk because it has limited operating resources and depends on external capital to fund development and commercialization. The business also carries execution risk from its transition away from legacy products, plus market and regulatory risk inherent in pharmaceutical development, OTC conversion, and distribution.
- Going concern uncertaintyVaikutus: KriittinenTodennäköisyys: Korkea
The company has reported negative operating cash flow and limited cash resources, creating doubt about its ability to fund operations.
Kohdistuu: Corporate liquidity and continuity of operations
- Need for additional capitalVaikutus: KorkeaTodennäköisyys: Korkea
Development and commercialization require funding before new products can generate cash flow.
Kohdistuu - Regulatory and commercialization riskVaikutus: KorkeaTodennäköisyys: Korkea
OTC/nonprescription pharmaceutical products require regulatory clearance and market acceptance.
Kohdistuu: Product launch timing and adoption
- Transition away from legacy revenue streamsVaikutus: Korkea
Historical ED and device businesses were discontinued or assigned, removing established revenue sources.
Kohdistuu: Revenue base and operating scale
- OTC market liquidity and delisting riskVaikutus: KeskitasoTodennäköisyys: Korkea
Trading on OTC markets can reduce liquidity and investor access compared with a national exchange.
Kohdistuu: Capital raising and share price volatility
Kirjanpito
Harkinnanvaraiset erätLegacy subsidiaries and product lines are presented separately, changing how revenue and losses appear in continuing operations.
Vaikutus: Affects comparability of current-period results
Management must evaluate whether available resources are sufficient for the next twelve months.
Vaikutus: Influences disclosure and asset/liability presentation
The company cites judgment around legal and contingent matters, which can change reported liabilities.
Vaikutus: May affect reserves and expense recognition
The Vivus settlement and related note/security agreement required recognition of inventory, liabilities, and gains.
Vaikutus: Can create one-time gains or balance-sheet reclassifications
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Pelthos Therapeutics Inc.
PTHS · Biological Products, (No Diagnostic Substances)
Mangoceuticals, Inc
MGRX · Services-Misc Health & Allied Services, NEC
Vivos Therapeutics, Inc.
VVOS · Surgical & Medical Instruments & Apparatus
Vanda Pharmaceuticals Inc.
VNDA · Pharmaceutical Preparations
Semnur Pharmaceuticals, Inc.
SMNR · Pharmaceutical Preparations
electroCore, Inc.
ECOR · Electromedical & Electrotherapeutic Apparatus
Päivitetty: 24.9.2026